

|  |   |    |   |                          |                       |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|  |   |    |   | Application Number       | 10/559,982            |
|  |   |    |   | Filing Date              | February 2, 2006      |
|  |   |    |   | First Named Inventor     | Ruggero FARELLO       |
|  |   |    |   | Group Art Unit           | 1627                  |
|  |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|  |   |    |   | Confirmation No.         | 6583                  |
| Sheet  | 1 | of | 1 | Attorney Docket No.      | 373987-011US (102895) |

| OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS |                       |  |                          |    |
|---|-----------------------|--|--------------------------|----|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | Translation <sup>2</sup> |    |
|   |                       |  | Yes                      | No |
|   | C117                  | Macleod <i>et al.</i> , "Monoamine oxidase B inhibitors for early Parkinson's disease (review)," <i>Cochrane Database of Systematic Reviews</i> 2005, Issue 3, Art. No.: CD004898. (Exhibit A to 3 <sup>rd</sup> Declaration of C. Warren Olanow)  |                          |    |
|   | C118                  | Stocchi <i>et al.</i> , "Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study," <i>Ann. Neurol.</i> 68:18-27 (2010). (Exhibit B to 3 <sup>rd</sup> Declaration of C. Warren Olanow)   |                          |    |
|   | C119                  | Olanow, "Levodopa/Dopamine Replacement Strategies in Parkinson's Disease — Future Directions," <i>Mov. Disord.</i> 23(Suppl. 3): S613-S622 (2008). (Exhibit C to 3 <sup>rd</sup> Declaration of C. Warren Olanow)  |                          |    |
|   | C120                  | Olanow <i>et al.</i> , "Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications," <i>Lancet Neurology</i> 5:677-687 (2006). (Exhibit D to 3 <sup>rd</sup> Declaration of C. Warren Olanow)   |                          |    |
|   | C121                  | Lang <i>et al.</i> , "Progress In Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease," <i>Canadian J. Neurol. Sci.</i> 32:277-286 (2005). (Exhibit E to 3 <sup>rd</sup> Declaration of C. Warren Olanow)   |                          |    |
|   | C122                  | Newron Pharmaceuticals SpA, "Safinamide: Study 018 Top-Line Results," Investor and Analyst Call Presentation, November 4, 2010 (available online at <a href="http://www.newron.com">http://www.newron.com</a> ) ("Study 018 Presentation"). (Exhibit F to 3 <sup>rd</sup> Declaration of C. Warren Olanow) |                          |    |
|   | C123                  | Olanow <i>et al.</i> , "Parkinson's Disease And Other Movement Disorders," Chapter 372, in <i>Harrison's Principles of Internal Medicine</i> , 18th ed. (in press) (manuscript). (Exhibit G to 3 <sup>rd</sup> Declaration of C. Warren Olanow)  |                          |    |
|   | C124                  | Hely <i>et al.</i> , "The Sydney Multicenter Study of Parkinson's disease: The Inevitability of Dementia at 20 years," <i>Mov. Disord.</i> 6:837-844 (2008). (Exhibit H to 3 <sup>rd</sup> Declaration of C. Warren Olanow)  |                          |    |
|   |                       |  |                          |    |
|   |                       |  |                          |    |

16227509.1.BUSINESS

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.